Weeks before Amgen, Inc. was scheduled to argue against a proposed US Federal Trade Commission injunction to block its acquisition of Horizon Therapeutics plc, the agency has suspended its review of the proposed merger to give the two sides time to negotiate a settlement. The FTC made a motion to withdraw the matter from adjudication, which its internal court approved on 23 August, stopping any further review of the transaction until 18 September.
FTC Is Ready To Negotiate Over Amgen/Horizon Merger
Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.
More from Legal & IP
More from Business
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.